Calidi Biotherapeutics (CLDI) Interest Expenses (2022 - 2025)
Calidi Biotherapeutics' quarterly Interest Expenses came in at $5000.0 in Q4 2025, down 95.33% year-on-year from $107000.0 in Q4 2024, and down 83.87% quarter-over-quarter from $31000.0 in Q3 2025.
Calidi Biotherapeutics has reported Interest Expenses for 4 years, with the latest figure at $5000.0 in Q4 2025.
- For the quarter ending Q4 2025, Interest Expenses fell 95.33% year-over-year to $5000.0; the trailing twelve-month figure through Dec 2025 stood at $99000.0 (down 81.14% YoY), and the FY2025 full-year result was $76000.0, down 86.45% from the prior year.
- Interest Expenses for Q4 2025 stood at $5000.0, down from $31000.0 in the prior quarter.
- The five-year high for Interest Expenses was $223000.0 in Q3 2023, with the low at -$252000.0 in Q4 2023.
- Average Interest Expenses over 4 years is $80857.1, with a median of $99000.0 recorded in 2022.
- Peak annual rise in Interest Expenses reached 668.97% in 2023, while the deepest fall reached 352.0% in 2023.
- Tracing CLDI's Interest Expenses over 4 years: stood at $100000.0 in 2022, then tumbled by 352.0% to -$252000.0 in 2023, then jumped by 142.46% to $107000.0 in 2024, then slumped by 95.33% to $5000.0 in 2025.
- The last three Interest Expenses figures came in at $5000.0 (Q4 2025), $31000.0 (Q3 2025), and $29000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 12.90 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | -332,000.00 |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Calidi Biotherapeutics | - | - | - | 5,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Sep 30, 2025 | 31,000.00 |
| Sep 30, 2025 | 31,000.00 |
| Jun 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 29,000.00 |
| Mar 31, 2025 | 34,000.00 |
| Mar 31, 2025 | 34,000.00 |
| Dec 31, 2024 | 107,000.00 |
| Dec 31, 2024 | 107,000.00 |
| Sep 30, 2024 | 98,000.00 |
| Sep 30, 2024 | 98,000.00 |
| Jun 30, 2024 | 165,000.00 |
| Jun 30, 2024 | 165,000.00 |
| Mar 31, 2024 | 155,000.00 |
| Mar 31, 2024 | 155,000.00 |
| Dec 31, 2023 | -252,000.00 |
| Dec 31, 2023 | -252,000.00 |
| Sep 30, 2023 | 223,000.00 |
| Sep 30, 2023 | 223,000.00 |
| Jun 30, 2023 | 208,000.00 |
| Jun 30, 2023 | 208,000.00 |
| Mar 31, 2023 | 200,000.00 |
| Mar 31, 2023 | 200,000.00 |
| Dec 31, 2022 | 100,000.00 |
| Dec 31, 2022 | 100,000.00 |
| Sep 30, 2022 | 29,000.00 |
| Sep 30, 2022 | 29,000.00 |